In 2006, the FDA sent a warning letter to the compounder that cited, among other things, concerns about marketing anesthetic creams and potential microbial contamination associated with splitting and repackaging Avastin.

FORBES: How The Compounding Scandal Benefits One Drugmaker

Research scientists used microarrays to investigate how the microbial community responded to the contamination and how they may have consumed much of the oil and gas.

FORBES: Guest post written by Aaron Peacock